MoonLake Immunotherapeutics vs Spyre Therapeutics
MLTX and SYRE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MLTX and SYRE compare
Spyre Therapeutics is the larger company, worth 8.5 times as much as MoonLake Immunotherapeutics ($8.5B against $1.0B).
Spyre Therapeutics scores higher on the StockData Score (7 against 1 for MoonLake Immunotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MLTX | SYRE |
|---|---|---|
| Size and price | ||
| Market cap | $1.0B | $8.5B |
| Share price | $11.78 | $96.56 |
| Change, 1 year | 22.6% | 305% |
| Change, 5 years | 19.0% | −47.2% |
| Beta (5Y) | 0.76 | 1.47 |
| Employees | 130 | 102 |
| StockData Score | ||
| Total score | 1 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 2.3× (better) | 7.7× |
| FCF yield | −22.5% | – |
| Profitability | ||
| Return on equity | −67.4% | −23.0% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −26.6× | – |
| Current ratio | 12.56 | 18.53 (better) |
| Altman Z-score | 2.23 | 70.18 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 86.3% | 109% |
| Held by insiders | 59.9% | 20.4% |
| Insider net buying, 12 months | −$83.0M (better) | −$437M |
| Short interest, % of float | 23.6% | 18.3% |
Go deeper
- MLTX stock overview
- MLTX income statement
- MLTX valuation and score
- SYRE stock overview
- SYRE income statement
- SYRE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.